Graciela Hernandez
Family · Ventura, CANPI 1952547564
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,070 of the $20,940 with a category attached, or 81.5%. It is spread thinly across 43 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $8,189 and has fallen 54.0% since, to $3,765 in 2025. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 582 payments — averaging $35.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$3K
- AstraZeneca$3K
- Novo Nordisk$3K
- Amgen$2K
- Lilly USA, LLC$1K
- Abbott$854
- plus $7K from 37 others
What the payments were for
- Speaking & faculty fees$3,55217%
- Travel & lodging$650%
- Food & beverage$17,07082%
- Education$2531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,940 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 115 | $109,985 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 41 | $94,630 |
| JardianceEmpagliflozin | 31 | $38,025 |
| FarxigaDapagliflozin Propanediol | 37 | $29,267 |
| TrulicityDulaglutide | 20 | $23,111 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $19,632 |
| TradjentaLinagliptin | 14 | $13,162 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 16 | $7,819 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $7,296 |
| LyricaPregabalin | 12 | $7,138 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 15 | $1,954 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $938 |
| Estradiol | 13 | $549 |
| Atorvastatin Calcium | 47 | $458 |
| Terconazole | 11 | $423 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $3,086 | $109,985115 claims |
| AmgenEvenity (2 Syringes) | $1,829 | $94,63041 claims |
| Boehringer IngelheimJardiance, Tradjenta | $759 | $51,18745 claims |
| AstraZenecaFarxiga | $3,233 | $29,26737 claims |
| Lilly USA, LLCTrulicity | $1,373 | $23,11120 claims |
| PfizerLyrica | $277 | $7,13812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Ventura
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.